Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kristian Reich

Showing results (111-120 of 265) with videos related to

Pageof 27
Sort By:
Dermatology (Basel, Switzerland)|September 16, 2009
Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasisKristian Reich, Siegfried Segaert, Peter Van de Kerkhof, et al.
European Journal of Dermatology : EJD|April 7, 2020
Fumaric acid esters for the treatment of psoriasis in Germany: characterising patients in routine careUlrich Mrowietz, Christina Sorbe, Kristian Reich, et al.
Dermatology (Basel, Switzerland)|July 15, 2010
Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS TrialKristian Reich, Jean-Paul Ortonne, Urs Kerkmann, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|December 28, 2021
Molecular diagnostics in dermatology: An online survey to study usage, obstacles and requirements in GermanyLinda Tizek, Barbara Schuster, Christoffer Gebhardt, et al.
Journal of the American Academy of Dermatology|October 12, 2010
Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trialKristian Reich, James Signorovitch, Karthik Ramakrishnan, et al.
Journal of the American Academy of Dermatology|July 6, 2010
Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendationsMark Lebwohl, Newman Yeilding, Philippe Szapary, et al.
The Journal of Dermatological Treatment|August 18, 2022
Response to fumaric acid esters for plaque type psoriasis in real-world practice is largely independent of patient characteristics at baseline - a multivariable regression analysis from the German Psoriasis Registry PsoBestKristian Reich, Ulrich Mrowietz, Christina Sorbe, et al.
Skin Pharmacology and Physiology|September 6, 2025
Effects of a gel containing the defined microalgae extract Spiralin® on the skin microbiome and clinical activity in atopic dermatitis - a double-blind, intraindividual vehicle-controlled proof-of-concept studyKristian Reich, Natalie Trettel, Jeremias L K Reich, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 19, 2022
Molekulardiagnostik in der Dermatologie: Eine Online-Umfrage zur Untersuchung von Nutzung, Hürden und Anforderungen in DeutschlandLinda Tizek, Barbara Schuster, Christoffer Gebhardt, et al.
American Journal of Clinical Dermatology|September 10, 2020
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 StudyKristian Reich, April W Armstrong, Peter Foley, et al.
Pageof 27

Showing results (111-120 of 265) with videos related to

Sort By:
Pageof 27
Dermatology (Basel, Switzerland)|September 16, 2009
Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasisKristian Reich, Siegfried Segaert, Peter Van de Kerkhof, et al.
European Journal of Dermatology : EJD|April 7, 2020
Fumaric acid esters for the treatment of psoriasis in Germany: characterising patients in routine careUlrich Mrowietz, Christina Sorbe, Kristian Reich, et al.
Dermatology (Basel, Switzerland)|July 15, 2010
Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS TrialKristian Reich, Jean-Paul Ortonne, Urs Kerkmann, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|December 28, 2021
Molecular diagnostics in dermatology: An online survey to study usage, obstacles and requirements in GermanyLinda Tizek, Barbara Schuster, Christoffer Gebhardt, et al.
Journal of the American Academy of Dermatology|October 12, 2010
Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trialKristian Reich, James Signorovitch, Karthik Ramakrishnan, et al.
Journal of the American Academy of Dermatology|July 6, 2010
Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendationsMark Lebwohl, Newman Yeilding, Philippe Szapary, et al.
The Journal of Dermatological Treatment|August 18, 2022
Response to fumaric acid esters for plaque type psoriasis in real-world practice is largely independent of patient characteristics at baseline - a multivariable regression analysis from the German Psoriasis Registry PsoBestKristian Reich, Ulrich Mrowietz, Christina Sorbe, et al.
Skin Pharmacology and Physiology|September 6, 2025
Effects of a gel containing the defined microalgae extract Spiralin® on the skin microbiome and clinical activity in atopic dermatitis - a double-blind, intraindividual vehicle-controlled proof-of-concept studyKristian Reich, Natalie Trettel, Jeremias L K Reich, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|March 19, 2022
Molekulardiagnostik in der Dermatologie: Eine Online-Umfrage zur Untersuchung von Nutzung, Hürden und Anforderungen in DeutschlandLinda Tizek, Barbara Schuster, Christoffer Gebhardt, et al.
American Journal of Clinical Dermatology|September 10, 2020
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 StudyKristian Reich, April W Armstrong, Peter Foley, et al.
Pageof 27